A Randomized Phase II Trial of Temozolomide (TMZ) with/without Recentin (AZD2171) in Patients with unresectable Stage IV Malignant Melanoma.

Study identifier:IRUS21710038

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Other

Official Title

A Randomized Phase II Trial of Temozolomide (TMZ) with/without Recentin (AZD2171) in Patients with unresectable Stage IV Malignant Melanoma.

Medical condition

Colorectal Cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria